The Journal of Urology
Volume 181, Issue 5 , Pages 2064-2070 , May 2009

Association of Nonsteroidal Anti-Inflammatory Drugs, Prostate Specific Antigen and Prostate Volume

  • Jay H. Fowke

      Affiliations

    • Vanderbilt Epidemiology Center, Vanderbilt University Medical Center, Nashville, Tennessee
    • Corresponding Author InformationCorrespondence: 2525 West End Ave., 6th Floor, Suite 600, Vanderbilt University Medical Center, Nashville, Tennessee 37203-1738 (telephone: 615-936-2903; FAX: 615-936-8291)
    • ,
  • Saundra S. Motley

      Affiliations

    • Vanderbilt Epidemiology Center, Vanderbilt University Medical Center, Nashville, Tennessee
    • ,
  • Joseph A. Smith Jr.

      Affiliations

    • Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee
    • ,
  • Michael S. Cookson

      Affiliations

    • Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee
    • ,
  • Raoul Concepcion

      Affiliations

    • Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee
    • Urology Associates, Nashville, Tennessee
    • ,
  • Sam S. Chang

      Affiliations

    • Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee
    • Financial interest and/or other relationship with Sanofi-Aventis.
    • ,
  • Susan Byerly

      Affiliations

    • Vanderbilt Epidemiology Center, Vanderbilt University Medical Center, Nashville, Tennessee

Received 12 September 2008

References 

  1. Roehrborn CG. Definition of at-risk patients: baseline variables. BJU Int. 2006;97(suppl.):7
  2. Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, Rittmaster RS. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE Trial. Eur Urol. 2007;54:1379
  3. Lucia MS, Torkko KC. Inflammation as a target for prostate cancer chemoprevention: pathological and laboratory rationale. J Urol. 2004;171:S30
  4. Palapattu GS, Sutcliffe S, Bastian PJ, Platz EA, De Marzo AM, Isaacs WB, et al. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis. 2005;26:1170
  5. Wang W, Bergh A, Damber JE. Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. Clin Cancer Res. 2005;11:3250
  6. Denkert C, Thoma A, Niesporek S, Weichert W, Koch I, Noske A, et al. Overexpression of cyclooxygenase-2 in human prostate carcinoma and prostatic intraepithelial neoplasia-association with increased expression of Polo-like kinase-1. Prostate. 2007;67:361
  7. Shahedi K, Lindstrom S, Zheng SL, Wiklund F, Adolfsson J, Sun J, et al. Genetic variation in the COX-2 gene and the association with prostate cancer risk. Int J Cancer. 2006;119:668
  8. Mahmud S, Franco E, Aprikian A. Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer. 2004;90:93
  9. Platz EA, Rohrmann S, Pearson JD, Corrada MM, Watson DJ, De Marzo AM, et al. Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging. Cancer Epidemiol Biomarkers Prev. 2005;14:390
  10. Jacobs EJ, Rodriguez C, Mondul AM, Connell CJ, Henley SJ, Calle EE, et al. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J Natl Cancer Inst. 2005;97:975
  11. Garcia Rodriguez LA, Gonzalez-Perez A. Inverse association between nonsteroidal anti-inflammatory drugs and prostate cancer. Cancer Epidemiol Biomarkers Prev. 2004;13:649
  12. Smith MR, Manola J, Kaufman DS, Oh WK, Bubley GJ, Kantoff PW. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol. 2006;24:2723
  13. Pruthi RS, Derksen JE, Moore D, Carson CC, Grigson G, Watkins C, et al. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Clin Cancer Res. 2006;12:2172
  14. Kulkarni GS, Al-Azab R, Lockwood G, Toi A, Evans A, Trachtenberg J, et al. Evidence for a biopsy derived grade artifact among larger prostate glands. J Urol. 2006;175:505
  15. Fowke JH, Signorello LB, Chang SS, Matthews CE, Buchowski MS, Cookson MS, et al. Effects of obesity and height on PSA and percent free PSA levels among African-American and Caucasian men. Cancer. 2006;107:2361
  16. Yang CC, Ku CY, Wei S, Shiau CW, Chen CS, Pinzone JJ, et al. Peroxisome proliferator-activated receptor γ-independent repression of prostate-specific antigen expression by thiazolidinediones in prostate cancer cells. Mol Pharmacol. 2006;69:1564
  17. Conte D, Romanelli F, Fillo S, Guidetti L, Isidori A, Franceschi F, et al. Aspirin inhibits androgen response to chorionic gonadotropin in humans. Am J Physiol Endocrinol Metab. 1999;277:E1032
  18. Liu XH, Kirschenbaum A, Yu K, Yao S, Levine AC. Cyclooxygenase-2 suppresses hypoxia-induced apoptosis via a combination of direct and indirect inhibition of p53 activity in a human prostate cancer cell line. J Biol Chem. 2005;280:3817
  19. Makarov DV, Trock BJ, Humphreys EB, Mangold LA, Walsh PC, Epstein JI, et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology. 2007;69:1095

 Study received Vanderbilt University institutional review board approval.

PII: S0022-5347(09)00053-6

doi: 10.1016/j.juro.2009.01.031

The Journal of Urology
Volume 181, Issue 5 , Pages 2064-2070 , May 2009

Article Tools